AARP: Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiations

Their “denial of these petitions brings an end to these six companies’ efforts to dismantle the Medicare Negotiation program,” says Michael Lieberman, counsel for Patients For Affordable Drugs at Fairmark Partners LLP.

“Six of the largest pharmaceutical companies in the world, represented by some of the largest law firms in the world, raised a wide variety of legal arguments against the program,” he says. “Now, courts at all three levels of the federal system have uniformly rejected those arguments, confirming that pharma companies do not have a constitutional right to charge the government exorbitant prices for prescription drugs.”